{
  "run": {
    "generated_at": "2026-01-04T09:05:31.160371+00:00"
  },
  "patient_vector": [
    0.0,
    0.0,
    0.0,
    0.0,
    0.0,
    1.0,
    0.0
  ],
  "top_10": [
    {
      "nct_id": "NCT04123379",
      "fit": 1.0,
      "primary_moa": "IO pathway (nivolumab)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.9,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT06631079",
      "fit": 1.0,
      "primary_moa": "IO pathway (pd-1)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.9,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT03878979",
      "fit": 1.0,
      "primary_moa": "IO pathway (nivolumab)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.9,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT02422979",
      "fit": 1.0,
      "primary_moa": "IO pathway (immunotherapy)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.9,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT06108479",
      "fit": 1.0,
      "primary_moa": "IO pathway (pembrolizumab)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.9,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT04164979",
      "fit": 0.707107,
      "primary_moa": "VEGF pathway (cabozantinib)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.9,
        "her2": 0.0,
        "io": 0.9,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT06331130",
      "fit": 0.0,
      "primary_moa": "HER2-targeted therapy (Trastuzumab deruxtecan with Zanidatamab)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.95,
        "io": 0.0,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT04284969",
      "fit": 0.0,
      "primary_moa": "DNA Damage Repair (PARP + ATR inhibitors)",
      "moa_vector": {
        "ddr": 0.95,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.0,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT04001023",
      "fit": 0.0,
      "primary_moa": "DNA Damage Repair (PARP inhibitor Olaparib)",
      "moa_vector": {
        "ddr": 0.9,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.0,
        "her2": 0.0,
        "io": 0.0,
        "efflux": 0.0
      }
    },
    {
      "nct_id": "NCT01000259",
      "fit": 0.0,
      "primary_moa": "VEGF Angiogenesis Inhibition (Bevacizumab)",
      "moa_vector": {
        "ddr": 0.0,
        "mapk": 0.0,
        "pi3k": 0.0,
        "vegf": 0.9,
        "her2": 0.0,
        "io": 0.0,
        "efflux": 0.0
      }
    }
  ],
  "notes": [
    "This is a synthetic edge-case prototype for discrimination testing."
  ]
}